JP2005533007A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005533007A5 JP2005533007A5 JP2003579741A JP2003579741A JP2005533007A5 JP 2005533007 A5 JP2005533007 A5 JP 2005533007A5 JP 2003579741 A JP2003579741 A JP 2003579741A JP 2003579741 A JP2003579741 A JP 2003579741A JP 2005533007 A5 JP2005533007 A5 JP 2005533007A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- het
- cycloalkyl
- unsubstituted
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000000217 alkyl group Chemical group 0.000 claims 92
- 125000000753 cycloalkyl group Chemical group 0.000 claims 42
- 125000003342 alkenyl group Chemical group 0.000 claims 22
- 125000005843 halogen group Chemical group 0.000 claims 21
- 125000000304 alkynyl group Chemical group 0.000 claims 19
- 229910052799 carbon Inorganic materials 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 claims 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 125000004404 heteroalkyl group Chemical group 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 125000003302 alkenyloxy group Chemical group 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 210000001130 astrocyte Anatomy 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000002829 reductive effect Effects 0.000 claims 1
- 125000004001 thioalkyl group Chemical group 0.000 claims 1
- 0 C*(C)(C1CCCCCCCC1)N(C)CC(C1CCCCCCCC1)C1CCCCCCCCC1 Chemical compound C*(C)(C1CCCCCCCC1)N(C)CC(C1CCCCCCCC1)C1CCCCCCCCC1 0.000 description 2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36842402P | 2002-03-27 | 2002-03-27 | |
| PCT/US2003/009225 WO2003082198A2 (en) | 2002-03-27 | 2003-03-26 | Methods of treatment with lxr modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005533007A JP2005533007A (ja) | 2005-11-04 |
| JP2005533007A5 true JP2005533007A5 (enExample) | 2006-06-08 |
Family
ID=28675488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003579741A Ceased JP2005533007A (ja) | 2002-03-27 | 2003-03-26 | Ｌｘｒ調節因子を用いる治療方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20050171084A1 (enExample) |
| EP (1) | EP1511483A4 (enExample) |
| JP (1) | JP2005533007A (enExample) |
| AU (1) | AU2003220521A1 (enExample) |
| WO (1) | WO2003082198A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1497270A4 (en) * | 2002-03-27 | 2006-01-04 | Smithkline Beecham Corp | AMID COMPOUNDS AND METHOD FOR THEIR USE |
| JP2005521721A (ja) * | 2002-03-27 | 2005-07-21 | スミスクライン・ビーチャム・コーポレイション | 酸およびエステル化合物ならびにその使用方法 |
| US7323494B2 (en) * | 2002-03-27 | 2008-01-29 | Smithkline Beecham Corporation | Compounds and methods |
| AU2003226094A1 (en) * | 2002-03-27 | 2003-10-13 | Smithkline Beecham Corporation | Compounds and methods |
| WO2004113533A1 (ja) * | 2003-06-24 | 2004-12-29 | Sumitomo Chemical Company, Limited | 肝臓Ｘ受容体αスプライシング変異体タンパク質、その遺伝子及びそれらの利用 |
| US7390835B2 (en) * | 2003-10-30 | 2008-06-24 | Merck & Co., Inc. | Aralkyl amines as cannabinoid receptor modulators |
| JP2007516258A (ja) * | 2003-12-12 | 2007-06-21 | ワイス | 心臓血管の疾患治療に有用なキノリン誘導体 |
| US20060069076A1 (en) * | 2004-07-01 | 2006-03-30 | Yu Sun | LXR/RXR-related methods and compositions |
| AU2006272922A1 (en) | 2005-07-22 | 2007-02-01 | Amgen Inc. | Aniline sulfonamide derivatives and their uses |
| US8389739B1 (en) | 2006-10-05 | 2013-03-05 | Orphagen Pharmaceuticals | Modulators of retinoid-related orphan receptor gamma |
| US8497122B2 (en) | 2008-04-11 | 2013-07-30 | Washington University | Biomarkers for Niemann-pick C disease and related disorders |
| WO2012142039A1 (en) * | 2011-04-15 | 2012-10-18 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
| AU2015204572B2 (en) * | 2014-01-10 | 2020-07-30 | Inspirna, Inc. | LXR agonists and uses thereof |
| KR101947976B1 (ko) | 2015-12-15 | 2019-02-13 | 아스트라제네카 아베 | 이소인돌 화합물 |
| EP3638661A1 (en) | 2017-06-14 | 2020-04-22 | Astrazeneca AB | 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators |
| EP3713575A4 (en) | 2017-11-21 | 2021-08-25 | Rgenix, Inc. | POLYMORPHS AND THEIR USES |
| US20200038410A1 (en) * | 2018-07-26 | 2020-02-06 | Loyola University Chicago | Methods for treating neuropathy |
| JP7689964B2 (ja) | 2019-12-13 | 2025-06-09 | インスピルナ，インコーポレーテッド | 金属塩及びその使用 |
| EP4777094A1 (en) * | 2023-09-13 | 2026-07-22 | The Board of Trustees of the University of Illinois | Compositions for use in a method of treating a motor neuron disease or condition associated with a spg11 pathogenic variant |
| CN117224516A (zh) * | 2023-11-01 | 2023-12-15 | 上海市第六人民医院 | 激活lxr/rxr通路的试剂在制备治疗als的药物中的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR970006890B1 (ko) * | 1987-10-20 | 1997-04-30 | 오스카 세이야꾸 가부시끼가이샤 | 페닐카르복시산 유도체 및 그 염 |
| ATE236137T1 (de) * | 1996-02-02 | 2003-04-15 | Merck & Co Inc | Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit |
| US6696484B2 (en) * | 1997-10-31 | 2004-02-24 | University Of Chicago Office Of Technology And Intellectual Property | Method and compositions for regulation of 5-alpha reductase activity |
| KR20010031501A (ko) * | 1997-10-31 | 2001-04-16 | 추후제출 | 5-알파 환원효소 활성을 조절하는 방법 및 조성물 |
| US20030153541A1 (en) * | 1997-10-31 | 2003-08-14 | Robert Dudley | Novel anticholesterol compositions and method for using same |
| WO2000055318A2 (en) * | 1999-03-15 | 2000-09-21 | University Of British Columbia | Abc1 polypeptide and methods and reagents for modulating cholesterol levels |
| US20040137423A1 (en) * | 1999-03-15 | 2004-07-15 | Hayden Michael R. | Compositions and methods for modulating HDL cholesterol and triglyceride levels |
| US6316503B1 (en) * | 1999-03-15 | 2001-11-13 | Tularik Inc. | LXR modulators |
| IL129178A0 (en) * | 1999-03-25 | 2000-02-17 | Yeda Res & Dev | Induction of nerve generation |
| JP2002543216A (ja) * | 1999-04-30 | 2002-12-17 | アーチ ディベロップメント コーポレイション | ステロイド誘導体 |
| US20060025393A1 (en) * | 1999-04-30 | 2006-02-02 | Shutsung Liao | Steroid derivatives |
| EP1212065A4 (en) * | 1999-07-08 | 2004-02-11 | Tularik Inc | COMPILATIONS AND METHODS FOR INCREASING THE HDL CHOLESTEROL LEVEL |
| GB9917405D0 (en) * | 1999-07-23 | 1999-09-22 | Univ Dundee | Methods of treatment and drug screening methods |
| AU1291901A (en) * | 1999-09-01 | 2001-03-26 | University Of British Columbia, The | Compositions and methods for modulating hdl cholesterol and triglyceride levels |
| EP1239855A4 (en) * | 1999-12-13 | 2004-04-21 | Merck & Co Inc | METHOD FOR PREVENTING AND TREATING ARTERIOSCLEROSIS |
| US20030086923A1 (en) * | 1999-12-13 | 2003-05-08 | Sparrow Carl P. | Method for the prevention and/or treatment of atherosclerosis |
| DE60107449T2 (de) * | 2000-09-18 | 2005-12-08 | Glaxo Group Ltd., Greenford | Substituierte aminopropoxyarylderivate als lxr agonisten |
| WO2002062302A2 (en) * | 2001-02-08 | 2002-08-15 | The University Of Chicago | Steroidal derivatives |
| JP4309661B2 (ja) * | 2001-05-03 | 2009-08-05 | ザ ユニバーシティー オブ シカゴ | 肝臓ｘ受容体 |
| US20070197484A1 (en) * | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| US7078396B2 (en) * | 2001-05-03 | 2006-07-18 | Arch Development Corporation | Method of treating disorder related to high cholesterol concentration |
| AU2002304931A1 (en) * | 2001-06-08 | 2002-12-23 | University Of British Columbia | Methods for treating disorders of the nervous and reproductive systems |
| US7482366B2 (en) * | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| US7998986B2 (en) * | 2001-12-21 | 2011-08-16 | Exelixis Patent Company Llc | Modulators of LXR |
| AU2003226094A1 (en) * | 2002-03-27 | 2003-10-13 | Smithkline Beecham Corporation | Compounds and methods |
| US7323494B2 (en) * | 2002-03-27 | 2008-01-29 | Smithkline Beecham Corporation | Compounds and methods |
| US20050136421A1 (en) * | 2003-12-23 | 2005-06-23 | Hayden Michael R. | Methods and reagents for modulating cholesterol levels |
-
2003
- 2003-03-26 AU AU2003220521A patent/AU2003220521A1/en not_active Abandoned
- 2003-03-26 US US10/509,197 patent/US20050171084A1/en not_active Abandoned
- 2003-03-26 WO PCT/US2003/009225 patent/WO2003082198A2/en not_active Ceased
- 2003-03-26 JP JP2003579741A patent/JP2005533007A/ja not_active Ceased
- 2003-03-26 EP EP03716832A patent/EP1511483A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007127635A3 (en) | Diketo-piperazine and piperidine derivatives as antiviral agents | |
| JP2011507896A5 (enExample) | ||
| EP0189788B1 (de) | Synergistische Kombination von Flupirtin und nicht-steroidalen Antiphlogistika | |
| JP2013532652A5 (enExample) | ||
| NL300929I2 (nl) | Telotristat, desgewenst in de vorm van een farmaceutisch aanvaardbaar ester of zout, in het bijzonder telotristat ethyl, meer in het bijzonder het hippuraat zout van telotristat ethyl | |
| ATE365742T1 (de) | 4-aminothieno(2,3-d) pyrimidin -6-carbonitril- derivative zur verwendung als pde7 inhibitoren | |
| RU2010119645A (ru) | Замещенные гетероциклом пиперазинодигидротиенопиримидины | |
| WO2006098918A3 (en) | Substituted gamma lactams as therapeutic agents | |
| JP2011500621A5 (enExample) | ||
| EA201101243A1 (ru) | 3h-имидазо[4,5-c]пиридин-6-карбоксамиды в качестве противовоспалительных средств | |
| MXPA05010899A (es) | Derivados de 2-aminopirimidina y su uso medico. | |
| JP2012524055A5 (enExample) | ||
| JP2010536887A5 (enExample) | ||
| WO2009082818A8 (en) | Novel c-21-keto lupane derivatives preparation and use thereof | |
| BR112013014184A2 (pt) | compostos de triazina [1,2,4] triazolo [4,3-b][1,2,4], método de preparo e seu uso | |
| JP2014500295A5 (enExample) | ||
| GEP20105025B (en) | Pharmaceutical compositions for treatent of atherosclerosis and related conditions and use thereof for treatment of these diseases | |
| WO2011118976A3 (en) | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same | |
| RU2002111005A (ru) | Производные нафтиридина | |
| JP2012530758A5 (enExample) | ||
| SI2889033T1 (en) | Treatment of negative symptoms of schizophrenia with (R) -7-chloro-N- (chonylidin-3-yl) benzo (B) thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| JP2008502696A5 (enExample) | ||
| JP2005508955A5 (enExample) | ||
| RU2014120477A (ru) | Производные пиримидин-4-она и их применение в лечении, облегчении или профилактике вирусного заболевания | |
| SI3029039T1 (en) | Pharmaceutical formulations containing crystalline forms of (R) -7-chloro-N- (quinuclidin-3-yl) benzo (b) thiophene-2-carboxamide hydrochloride monohydrate |